Emerging human papillomavirus vaccines

Bibliography

• ZUR HAUSEN H: Papillomaviruses andcancer: from basic studies to clinical application. Nat. Rev. Cancer (2002) 5:342–350.
   Web of Science ®Google Scholar
• MYERS G, LU H, CALEF C, LEITNER T: Heterogeneity of papillomaviruses. Semin. Cancer Biol. (1996) 7(0:349–58.
   PubMed Web of Science ®Google Scholar
• DE VILLIERS EM, FAUQUET C, BROKER TR, BERNARD HU, ZUR HH: Classification of papillomaviruses. Virology (2004) 324(1):17–27.
   PubMed Web of Science ®Google Scholar
• BOSCH FX, LORINCZ A, MUNOZ N, MEIJER CJLM, SHAH KV: The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol (2002) 55(4):244–265.
   PubMed Web of Science ®Google Scholar
• MUNOZ N, BOSCH FX, DE SANJOSE S et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. IV.Eng. J. Med. (2003) 348(6):518–527.
   PubMed Web of Science ®Google Scholar
• GIROGLOU T, SAPP M, LANE C et al: Immunological analyses of human papillomavirus capsids. Vaccine (2001) 19(13-14):1783–1793.
   PubMed Web of Science ®Google Scholar
• PASTRANA DV, VASS WC, LOWY DR, SCHILLER JT: NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology (2001) 279(1):361–369.
   PubMed Web of Science ®Google Scholar
• HO GYF, BIERMAN R, BEARDSLEY L, CHANG CJ, BURK RD. Natural history of cervicovaginal papillomavirus infection in young women. IV.Eng. J. Med. (1998) 338:423–428.
   PubMed Web of Science ®Google Scholar
• BROKER TR, JIN G, CROOM-RIVERS A et al: Viral latency-the papillomavirus model. Dev. Biol (Basel) (2001) 106:443–451.
   PubMedGoogle Scholar
• FRAZER IH: Immunology of papillomavirus infection. Curr. Opin. Immunol (1996) 8: 484–491.
   Google Scholar
• CRUM CP, ABBOTT DW, QUADE BJ: Cervical cancer screening: from the papanicolaou smear to the vaccine era. Clin. Oncol. (2003) 21 (Suppl. 10):224–230.
   Google Scholar
• SHANTA V, KRISHNAMURTHI S, GAJALAKSHMI CK, SWAMINATHAN R, RAVICHANDRAN K: Epidemiology of cancer of the cervix: global and national perspective. J. Indian Med. Assoc. (2000) 98(2):49–52.
   PubMedGoogle Scholar
• WALBOOMERS JM, JACOBS MV, MANOS MM et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pothol. (1999) 189(1):12–19.
   PubMed Web of Science ®Google Scholar
• DUGGAN MA: A review of the natural history of cervical intraepithelial neoplasia. Gan To Kagaku Ryoho (2002) 29(Suppl. 1):176–193.
   PubMedGoogle Scholar
• HOWLEY PM, LOWY DR: Papillomaviruses and their replication. In: Field's Virology (4th Ed). DM Knipe, PM Howley, (Eds). Lippincott Williamson & Wilkins, Philadelphia (2001):2197–257.
   Google Scholar
• DUENSING S, MUNGER K: Centrosomes, genomic instability, and cervical carcinogenesis. Crit. Rev. Eukaryot. Gene Expr. (2003) 13(1):9–23.
   PubMed Web of Science ®Google Scholar
• KLINGELHUTZ AJ, FOSTER SA, MCDOUGALL JK: Telomerase activation by the E6 gene product of human papillomavirus Type 16. Nature (1996) 380:79–82.
   PubMed Web of Science ®Google Scholar
• CASTLE PE, SCHIFFMAN M, BRATTI MC et al.: A population-based study of vaginal human papillomavirus infection in hysterectomized women. J. Infect. Dis. (2004) 190(3):458–467.
   PubMed Web of Science ®Google Scholar
• EINSTEIN MH, KADISH AS: Anogenital neoplasia in AIDS. Curr. Opin. Oncol (2004) 16(5):455–462.
   PubMed Web of Science ®Google Scholar
• DALING JR, MADELEINE MM, JOHNSON LG et al.: Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer (2004) 101(2):270–280.
   PubMed Web of Science ®Google Scholar
• VAN RENSBURG EJ, VENTER EH, SIMSON IW: Human papillomavirus DNA in aerodigestive squamous carcinomas demonstrated by means of in situ hybridisation. S. Aft. Med. J. (1993) 83(7):516–518.
   PubMed Web of Science ®Google Scholar
• GILLISON ML, LOWY DR: A causal role for human papillomavirus in head and neck cancer. Lancet (2004) 363(9420):1488–1489.
   PubMed Web of Science ®Google Scholar
• GILLISON ML, KOCH WM, CAPONE RB et al.: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Nail Cancer Inst. (2000) 92(9):709–720.
   PubMed Web of Science ®Google Scholar
• ZHANG ZY, SDEK P, CAO J, CHEN WT: Human papillomavirus type 16 and 18 DNA in oral squamous cell carcinoma and normal mucosa. Int. J. Oral Maxillofac. Surg (2004) 33(1):71–74.
   PubMed Web of Science ®Google Scholar
• CAPONE RB, PM SI, KOCH WM et al: Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin. Cancer Res. (2000) 6(11):4171–4175.
   PubMed Web of Science ®Google Scholar
• SYRJANEN S: HPV infections and tonsillar carcinoma. J. Clin. Pothol (2004) 57(5):449–455.
   PubMed Web of Science ®Google Scholar
• PAZ IB, COOK N, ODOM-MARYON T, XIE Y, WILCZYNSKI SP: Human papillomavirus (HPV) in head and neck cancer - an association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer (1997) 79:595–604.
   PubMed Web of Science ®Google Scholar
• SHIN KH, PARK KH, HONG HJ et al.: Prevalence of microsatellite instability, inactivation of mismatch repair genes, p53 mutation, and human papillomavirus infection in Korean oral cancer patients. Int. J. Oncol (2002) 21:297–302.
   PubMed Web of Science ®Google Scholar
• MOUNTS P, SHAH KV, KASHIMA H: Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx. Proc. Nail Acad. Sci. USA (1982) 79:5424–5429.
   Web of Science ®Google Scholar
• SYRJANEN S, PURANEN M: Human papillomavirus infections in children: the potential role of maternal transmission. Crit. Rev. Oral Biol. Med. (2000) 11(2):259–274.
   PubMedGoogle Scholar
• MAJEWSKI S, JABLONSKA S, ORTH G: Epidermodysplasia verruciformis. Immunological and nonimmunological surveillance mechanisms: role in tumor progression. Clin. Dermatol (1997) 15:321–334.
   PubMed Web of Science ®Google Scholar
• TIEBEN LM, BERKHOUT RJ, SMITS HL et al.: Detection of epidermodysplasia verruciformis-like human papillomavirus types in malignant and premalignant skin lesions of renal transplant recipients. Br. J. Dermatol (1994) 131(2):226–230.
   PubMed Web of Science ®Google Scholar
• DE VILLIERS EM, LAVERGNE D, MCLAREN K, BENTON EC: Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. Int. J. Cancer (1997) 73(3):356–361.
   PubMed Web of Science ®Google Scholar
• KUTLER DI, WREESMANN VB, GOBERDHAN A et el.: Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J. Nail Cancer Inst. (2003) 95(22):1718–1721.
   PubMed Web of Science ®Google Scholar
• CHERRY-PEPPERS G, DANIELS CO, MEEKS V, SANDERS CF, REZNIK D: Oral manifestations in the era of HAART. J. Natl. Med. Assoc. (2003) 95:21S–32S.
   Google Scholar
• NICHOLLS PK, STANLEY MA: The immunology of animal papillomaviruses. Vet. Immunol. Immunopathol (2000) 73(2):101–127.
   PubMed Web of Science ®Google Scholar
• BAKER GE, TYRING SK: Therapeutic approaches to papillomavirus infections. DermatolClin. (1997) 15(2):331–340.
   Google Scholar
• BERNARD HU: Established and potential strategies against papillomavirus infections. J. Antimicrob. Chemother. (2004) 53(2):137–139.
   PubMed Web of Science ®Google Scholar
• SNOECK R, NOEL JC, MULLER C, DE CLERCQ E, BOSSENS M: Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J. Med. Virol (2000) 60(2):205–209.
   PubMed Web of Science ®Google Scholar
• BELL MC, CROWLEY-NO-WICK P, BRADLOW HL et al.: Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. GynecoL Oncol (2000) 78(2):123–129.
   PubMed Web of Science ®Google Scholar
• GARLAND SM: Imiquimod. Curr. Opin. Infect. Dis. (2003) 16(2):85–89.
   PubMed Web of Science ®Google Scholar
• FOLLEN M, MEYSKENS FL Jr., ALVAREZ RD et al.: Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers. Cancer (2003) 98(Suppl. 9):2044–2051.
   PubMed Web of Science ®Google Scholar
• IYER RP, MARQUIS J, BONNEZ W: ORI-1001. Anti-papilloma virus oligonucleotide. Drugs fir. (2002) 27:546–557.
   Web of Science ®Google Scholar
• KOUTSKY LA, AULT KA, WHEELER CM et al.: A controlled trial of a human papillomavirus Type 16 vaccine. N Eng. J. Med. (2002) 347(21):1645–1651.
   PubMed Web of Science ®Google Scholar
• SCHILLER JT, LOWY DR: Papillomavirus-like particle vaccines. J. Nail. Cancer Inst. Monogr. (2000) 2000(28):50–54.
   Google Scholar
• BILLICH A: HPV vaccine MedImmune/ GlaxoSmithKline. Curr. Opin. Investig. Drugs (2003) 4(2):210–213.
   PubMedGoogle Scholar
• FIFE KH, WHEELER CM, KOUTSKY LA et al.: Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women. Vaccine (2004) 22(21-22):2943–2952.
   PubMed Web of Science ®Google Scholar
• ZHANG LF, ZHOU J, CHEN S et al: HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine (2000) 18(11-12):1051–1058.
   PubMed Web of Science ®Google Scholar
• HARPER DM, FRANCO EL, WHEELER C et al.: Efficacy of a bivalent Li virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 364:1757–1765.
   PubMed Web of Science ®Google Scholar
• SUZICH JA, GHIM SJ, PALMER-HILL FJ et al.: Systemic immunization with papillomavirus Li protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA (1995) 92:11553–11557.
   PubMed Web of Science ®Google Scholar
• BREITBURD F, KIRNBAUER R, HUBBERT NL et al.: Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Wrol. (1995) 69:3959–3963.
   Google Scholar
• KIRNBAUER R, CHANDRACHUD LM, O'Neil BW et al: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology (1996) 219:37–44.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN ND, REED CA, CLADEL NM, HAN R, KREIDER JW: Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. j Virol (1996)70:960–965.
   Google Scholar
• LACEY CJ, THOMPSON HS, MONTEIRO EF et al.: Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J. Infect. Dis. (1999) 179(3):612–618.
   PubMed Web of Science ®Google Scholar
• THOMPSON HS, DAVIES ML, HOLDING FP et al.: Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine (1999) 17(1):40–49.
   PubMed Web of Science ®Google Scholar
• HUNTS: Technology evaluation: HspE7, StressGen Biotechnologies Corp. Curr. Opin. Md. Ther. (2001) 3(4):413–417.
   PubMed Web of Science ®Google Scholar
• KAWANA K, YASUGI T, KANDA T et al: Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine (2003) 21(27-30):4256–4260.
   PubMed Web of Science ®Google Scholar
• WADLER S, LEVY D, FREDERICKSON HL et al.: A Phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. GynecoL Oncol (2004) 92(3):957–964.
   PubMed Web of Science ®Google Scholar
• KLENCKE B, MATIJEVIC M, URBAN RG et al.: Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin. Cancer Res. (2002) 8(5):1028–1037.
   PubMed Web of Science ®Google Scholar
• ADAMS M, BORYSIEWICZ L, FIANDER A et al.: Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine (2001) 19(17-19):2549–2556.
   PubMed Web of Science ®Google Scholar
• BALDWIN PJ, VAN DER BURG SH, BOS WELL CM et al.: Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin. Cancer Res. (2003) 9(105205–5313.
   Google Scholar
• CORONA GUTIERREZ CM, TINOCO A, NAVARRO T et al: Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum. Gene Ther. (2004) 15(5):421–431.
   PubMed Web of Science ®Google Scholar
• FERRARA A, NONN M, SEHR P et al: Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients./ Cancer Res. Clin. Oncol (2003) 129(9):521–530.
   PubMed Web of Science ®Google Scholar
• ADAMS M, NAVABI H, JASANI B et al.: Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I] :poly [C(12)-LJ] (Ampligen R). Vaccine (2003) 21(7-8):787–790.
   PubMed Web of Science ®Google Scholar
• FRAZER IH: Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol (2004) 4(1):46–54.
   PubMed Web of Science ®Google Scholar
• HU J, CLADEL NM, PICKEL MD, CHRISTENSEN ND: Amino acid residues in the carboxy-terminal region of cottontail rabbit papillomavirus E6 influence spontaneous regression of cutaneous papillomas. j ViroL (2002) 76(23):11801–11808.
   PubMed Web of Science ®Google Scholar
• SCOTT M, STITES DP, MOSCICKI AB: Thl cytokine patterns in cervical human papillomavirus infection. Clin. Diagn. Lab Immunol. (1999) 6(5):751–755.
   PubMedGoogle Scholar
• BONAGURA VR., HATAM L, DEVOTI J, ZENG F, STEINBERG BM: Recurrent respiratory papillomatosis: altered CD8(+) 16 T-cell subsets and T(H)1/T(H)2 cytokine imbalance. Clin. ImmunoL (1999) 93(3):302–311.
   PubMed Web of Science ®Google Scholar
• SHOPE RE: Immunization of rabbits to infectious papillomatosis. J. Exp. Med. (1937) 65:219–231.
   PubMedGoogle Scholar
• BELL JA, SUNDBERG JP, GHIM S, NEWSOME J, JENSON AB, SCHLEGEL R: A formalin-inactivated vaccine protects against mucosal papillomavirus infection: A canine model. Pathobiology (1994) 62(4):194–198.
   PubMed Web of Science ®Google Scholar
• JARRETT WFH, O'NEIL BW, GAUKROGER JM, SMITH KT LAIRD HM, CAMPO MS: Studies on vaccination against papillomaviruses: The immunity after infection and vaccination with bovine papillomaviruses of different types. Vet. Rec. (1990) 126:473–475.
   PubMed Web of Science ®Google Scholar
• YUAN H, ESTES PA, CHEN Y et al.: Immunization with a pentameric Li fusion protein protects against papillomavirus infection. J. Virol. (2001) 75(17):7848–7853.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN ND, KIRNBAUER R, SCHILLER JT, GHIM S-J, SCHLEGEL R, KREIDER JW: Human papillomavirus types 6 and 11 have antigenically distinct strongly-immunogenic conformationally-dependent neutralizing epitopes. Virology (1994) 205:329–335.
   PubMed Web of Science ®Google Scholar
• RODEN RBS, HUBBERT NL, KIRNBAUER R, CHRISTENSEN ND, LOWY DR, SCHILLER JT: Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J. Virol. (1996) 70: 3298–3301.
   Google Scholar
• PILACINSKI WP, GLASSMAN DL, GLASSMAN KF et al.: Development of a recombinant DNA vaccine against bovine papillomavirus infection in cattle. In: Papillomaviruses: Molecular and Clinical Aspects. TR Broker, PM Howley, (Eds.), Alan R. Liss, Inc., New York, (1985):257–271.
   Web of Science ®Google Scholar
• LIN Y-L, BORENSTEIN LA, AHMED R, WETTSTEIN FO: Cottontail rabbit papillomavirus Li protein-based vaccines: Protection is achieved only with a full-length, nondenatured product. J. Virol. (1993) 67:4154–4162.
   PubMed Web of Science ®Google Scholar
• CHANDRACHUD LM, GRINDLAY GJ, MCGARVIE GM et al.: Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology (1995) 211:204–208.
   PubMed Web of Science ®Google Scholar
• EMBERS ME, BUDGEON LR, PICKEL M, CHRISTENSEN ND: Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J. Virol. (2002) 76(19):9798–9805.
   PubMed Web of Science ®Google Scholar
• RODEN RBS, WEISSINGER EM, HENDERSON DW et al.: Neutralization of bovine papillomavirus by antibodies to Li and L2 capsid proteins. J. Virol. (1994) 68:7570–7574.
   PubMed Web of Science ®Google Scholar
• RODEN RB, YUTZY WH, FALLON R, INGLIS S, LOWY DR, SCHILLER JT: Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology (2000) 270(2):254–257.
   PubMed Web of Science ®Google Scholar
• KAWANA K, YOSHIKAWA H, TAKETANI Y, YOSHIIKE K, KANDA T: Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6.1 Virol. (1999) 73(7):6188–6190.
   Web of Science ®Google Scholar
• GREENSTONE HL, NIELAND JD, DE VISSER KE et al.: Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. NatL Acad. Sci. USA (1998) 95(4):1800–1805.
   PubMed Web of Science ®Google Scholar
• CHACKERIAN B, LOWY DR, SCHILLER JT: Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc. Natl. Acad. Sci. USA (1999) 96(5):2373–2378.
   PubMed Web of Science ®Google Scholar
• DONNELLY JJ, MARTINEZ D, JANSEN KU, ELLIS RW, MONTGOMERY DL, LIU MA: Protection against papillomavirus with a polynucleotide vaccine./ Infect. Dis. (1996) 173(2):314.
   Google Scholar
• SUNDARAM P, TIGELAAR RE, BRANDSMA JL: Intracutaneous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) Li gene protects against virus challenge. Vaccine (1997) 15:664–671.
   PubMed Web of Science ®Google Scholar
• STANLEY MA, MOORE RA, NICHOLLS PK et al.: Intra-epithelial vaccination with COPV Li DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine (2001) 19(20-22):2783–2792.
   PubMed Web of Science ®Google Scholar
• LIN YL, BORENSTEIN LA, SELVAKUMAR R, AHMED R, WETTSTEIN FO: Effective vaccination against papilloma development by immunization with Li or L2 structural protein of cottontail rabbit papillomavirus. Virology (1992) 187(2):612–619.
   PubMed Web of Science ®Google Scholar
• REUTER JD, VIVAS-GONZALEZ BE, GOMEZ D et al.: Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus Li protein provides complete protection against papillomavirus-induced disease./ Virol. (2002) 76(17):8900–8909.
   Web of Science ®Google Scholar
• ROBERTS A, REUTER JD, WILSON JH, BALDWIN S, ROSE JK: Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of Li protein./ Virol. (2004) 78(6):3196–3199.
   Web of Science ®Google Scholar
• MUNOZ N, BOSCH FX, CASTELLSAGUE X et al.: Against which human papillomavirus types shall we vaccinate and screen? the international perspective. Int. J. Cancer (2004) 111(2):278–285.
   PubMed Web of Science ®Google Scholar
• SELVAKUMAR R, BORENSTEIN LA, LIN YL, AHMED R, WETTSTEIN FO: Immunization with nonstructural proteins El and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J. Virol. (1995) 69(1):602–605.
   PubMed Web of Science ®Google Scholar
• MCGARVIE GM, GRINDLAY GJ, CHANDRACHUD LM, ONEIL BW, JARRETT WFH, CAMPO MS: T cell responses to BPV-4 E7 during infection and mapping of T cell epitopes. Virology (1995) 206:504–510.
   PubMed Web of Science ®Google Scholar
• HAN R, REED CA, CLADEL NM, CHRISTENSEN ND: Immunization of rabbits with cottontail rabbit papillomavirus El and E2 genes: protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection. Vaccine (2000) 18(20:2937–2944.
   PubMed Web of Science ®Google Scholar
• HAN R, CLADEL NM, REED CA, PENG X, CHRISTENSEN ND: Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus El, E2, E6, and E7 genes. Virol. (1999) 73(8):7039–7043.
   Web of Science ®Google Scholar
• MOORE RA, WALCOTT S, WHITE KL et al.: Therapeutic immunisation with COPV early genes by epithelial DNA delivery. Virology (2003) 314(2):630–635. 17
   PubMed Web of Science ®Google Scholar
• SUNDARAM P, TIGELAAR RE, XIAO W, BRANDSMA JL: Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge. Vaccine (1998) 16(6):613–623.
   PubMed Web of Science ®Google Scholar
• LEACHMAN SA, TIGELAAR RE, SHLYANKEVICH M et al.: Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus-rabbit model. J. Wrol. (2000) 74(108700–8708.
   Google Scholar
• HU J, HAN R, CLADEL NM, PICKEL MD, CHRISTENSEN ND: Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits. J. ViroL (2002) 76:6453–6459.
   PubMed Web of Science ®Google Scholar
• HAN R, REED CA, CLADEL NM, CHRISTENSEN ND: Intramuscular injection of plasmid DNA encoding cottontail rabbit papillomavirus El, E2, E6 and E7 induces T cell-mediated but not humoral immune responses in rabbits. Vaccine (1999) 17(11-12):1558–1566.
   PubMed Web of Science ®Google Scholar
• JENSEN ER, SELVAKUMAR R, SHEN H, AHMED R, WETTSTEIN FO, MILLER J: Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J. Virol (1997)71(10:8467–8474.
   Google Scholar
• SEWELL DA, DOUVEN D, PAN ZK, RODRIGUEZ A. PATERSON Y: Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch. Otolaryngol Head Neck Surg. (2004) 130(1):92–97.
   PubMed Web of Science ®Google Scholar
• BERMUDEZ-HUMARAN LG, CORTES-PEREZ NG, LE LOIR Y et al.: An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J. Med. MicrobioL (2004) 53(Pt 5):427–433.
   PubMed Web of Science ®Google Scholar
• LATHER, KIENY MP, DOTT K et al: Vaccination against polyoma- and papillomavirus-induced tumors using vaccinia recombinants expressing non-structural proteins. In: Vaccines for sexually transmitted diseases. A Mehens, RE Spier, (Eds.). Butterworths, London (1989):166–176.
   Google Scholar
• BRANDSMA JL, SHLYANKEVICH M, ZHANG L et al.: Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. J. Wrol. (2004) 78(1):116–123.
   Google Scholar
• LEACHMAN SA, SHYLANKEVICH M, SLADE MD et al.: Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J. ViroL (2002) 76(15):7616–7624.
   PubMed Web of Science ®Google Scholar
• HU J, CLADEL NM, WANG Z, HAN R, PICKEL MD, CHRISTENSEN ND: GM-CSF enhances protective immunity to cottontail rabbit papillomavirus E8 genetic vaccination in rabbits. Vaccine (2004) 22(9-101124–1130.
   Google Scholar
• LIU WJ, ZHAO KN, GAO FG, LEGGATT GR, FERNANDO GJ, FRAZER IH: Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine (2001) 20(5-6):862–869.
   PubMed Web of Science ®Google Scholar
• HAN R, CLADEL NM, REED CA et al.: DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J. Wrol. (2000) 74:9712–9716.
   Google Scholar
• MOCELLIN S, WANG E, MARINCOLA FM: Cytokines and immune response in the tumor microenvironment. j Immunother. (2001) 24(5):392–407.
   Web of Science ®Google Scholar
• PARDOLL DM: Cancer vaccines. Nat. Med. (1998) 4(Suppl. 5):525–531.
   PubMed Web of Science ®Google Scholar
• GLEW SS, CONNOR ME, SNIJDERS PJ et al.: HLA expression in pre-invasive cervical neoplasia in relation to human papilloma virus infection. Eur. j Cancer (1993) 29A(14):1963–1970.
   PubMed Web of Science ®Google Scholar
• SIKORSKI M, BOBEK M, ZRUBEK H, MARCINKIEWICZ J: Dynamics of selected MHC class I and II molecule expression in the course of HPV positive CIN treatment with the use of human recombinant IFN-gamma. Acta Obstet. Gynecol Scand. (2004) 83(3):299–307.
   PubMed Web of Science ®Google Scholar
• NAKAGAWA S, YOSHIKAWA H, YASUGI T et al.: Ubiquitous presence of E6 and E7 transcripts in human papillomavirus - Positive cervical carcinomas regardless of its type. J. Med. Virol. (2000) 62(2):251–256.
   PubMed Web of Science ®Google Scholar
• GAUKROGER JM, BRADLEY A, CHANDRACHUD L, JARRETT WFH, CAMPO MS: Interaction between bovine papillomavirus type 4 and cocarcinogens in the production of malignant tumours. J. Gen. Virol (1993) 74:2275–2280.
   PubMed Web of Science ®Google Scholar
• PARSONS RJ, KIDD JG: Oral papillomatosis of rabbits: A virus disease. J. Exp. Med. (1942) 77:233–250.
   Google Scholar
• CHAMBERS VC, EVANS CA: Canine oral papillomatosis. I. Virus assay and observations of the various stages of the experimental infection. Cancer Res. (1959) 19:1188–1195.
   PubMed Web of Science ®Google Scholar
• OLSON C: Cutaneous papillomatosis in cattle and other animals. Ann. IVY Acad. Sci. (1963) 108:1042–1056.
   PubMed Web of Science ®Google Scholar
• FELTKAMP MCW, SMITS HL, VIERBOOM MP et al.: Vaccination with cytotoxic T-lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type-16-transformed cells. Eur. j Immunol. (1993) 23(9):2242.
   PubMed Web of Science ®Google Scholar
• CHEN CH, JI H, SUFI KW, CHOTI MA, PARDOLL DM, WU TC: Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther. (1999) 6(12):1972–1981.
   PubMed Web of Science ®Google Scholar
• FRAZER IH, LEIPPE DM, DUNN LA et al.: Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease. Cancer Res. (1995) 5:2635–2639.
   Google Scholar
• DUNN LA, EVANDER M, TINDLE RW et al.: Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. Virology (1997) 235:94–103.
   PubMed Web of Science ®Google Scholar
• MONIZ M, LING M, HUNG CF, WU TC: HPV DNA vaccines. Front Biosci. (2003) 8:d55–d68.
   PubMed Web of Science ®Google Scholar
• TRIMBLE C, LIN CT, HUNG CF et al: Comparison of the CD8* T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 21(25-26):4036–4042.
   PubMed Web of Science ®Google Scholar
• KIM JW, HUNG CF, JUANG J et el.: Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther. (2004) 11(12):1011–1018.
   PubMed Web of Science ®Google Scholar
• HAN R, PENG X, REED CA et el.: Gene gun-mediated intracutaneous vaccination with papillomavirus E7 gene delays cancer development of papillomavirus-induced skin papillomas on rabbits. Cancer Detect. Prey. (2002) 26(6):458–467.
   PubMedGoogle Scholar
• ZWAVELING S, FERREIRA MOTA SC, NOUTA J et al.: Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol (2002) 169(1):350–358.
   PubMed Web of Science ®Google Scholar
• CHENG WF, HUNG CF, LIN KY et al.: CD8* T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther. (2003) 10(16):1311–1320.
   PubMed Web of Science ®Google Scholar
• CHEN L, MIZUNO MT, SINGHAL MC et al.: Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expression the E6 oncoprotein of human papillomavirus Type 16.1 Immunol (1992) 148:2617–2621.
   Web of Science ®Google Scholar
• MENEGUZZI G, CERNI C, KIENY MP, LATHE R: Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology (1991) 181:62–69.
   PubMed Web of Science ®Google Scholar
• HERD KA, HARVEY T, KHROMYKH AA, TINDLE RW: Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour. Virology (2004) 319(2):237–248.
   PubMed Web of Science ®Google Scholar
• CASSETTI MC, MCELHINEY SP, SHAHABI V et al.: Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine (2004) 22(3-4):520–527.
   PubMed Web of Science ®Google Scholar
• UN CT, HUNG CF, JUANG J et al.: Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. MoL Ther. (2003) 8(4):559–566.
   PubMed Web of Science ®Google Scholar
• HEINEMANN L, DILLON S, CRAWFORD A. BACKSTROM BT, HIBMA MH: Flow cytometric quantitation of the protective efficacy of dendritic cell based vaccines in a human papillomavirus Type 16 murine challenge model./ Virol. Methods (2004) 117(1):9–18.
   PubMed Web of Science ®Google Scholar
• LIU DW, TSAO YP, HSIEH CH et al.: Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J. Virol. (2000) 74(19):9083–9089.
   PubMed Web of Science ®Google Scholar
• JANSEN KU, ROSOLOWSKY M, SCHULTZ LD et al.: Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRP V-inducedpapilloma formation. Vaccine (1995) 13:1509–1512.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN ND, KREIDER JW, KAN NC, DIANGELO SL: The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology (1991) 181:572–579.
   PubMed Web of Science ®Google Scholar
• CAMPO MS, O'NEIL BW, GRINDLAY GJ, CURTIS F, KNOWLES G, CHANDRACHUD L: A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease. Virology (1997) 234: 261–266.
   Google Scholar
• KIM TW, HUNG CF, ZHENG M et al.: A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8* T-cell immune response. J. Biomed. Sci. (2004) 11(4):493–499.
   PubMed Web of Science ®Google Scholar
• KIM TW, HUNG CF, KIM JW et al.: Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum. Gene Ther. (2004) 15(2):167–177.
   PubMed Web of Science ®Google Scholar
• HUNG CF, CHENG WF, HE L et al.: Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res. (2003) 63(10):2393-2398. 141. WU TC, GUARNIERI FG, STAVELEY-O'CARROLL KF et al.: Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Nail. Acad. Sci. USA (1995) 92(25):11671–11675.
   PubMed Web of Science ®Google Scholar
• CHENG WF, HUNG CF, LEE CN et al.: Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways. Eur. J. Immunol (2004) 34(7):1892–1900.
   PubMed Web of Science ®Google Scholar
• CHENG WF, HUNG CH, CHAT CY et al.: Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen./ Virol. (2001) 75(5):2368–2376.
   Web of Science ®Google Scholar
• DAEMEN T, PRIES F, BUNGENER L, KRAAK M, REGTS J, WILSCHUT J: Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther. (2000) 7(21):1859–1866.
   PubMed Web of Science ®Google Scholar
• KIM TY, MYOUNG HJ, KIM JH et al.: Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4* and CD8* T cells in protection. Cancer Res. (2002) 62(24):7234–7240.
   PubMed Web of Science ®Google Scholar
• VELDERS MP, WEIJZEN S, EIBEN GL et al.: Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J. Immunol (2001) 166(9):5366–5373.
   PubMed Web of Science ®Google Scholar
• FELTKAMP MCW, VREUGDENHIL GR, VIERBOOM RPM et al.: Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. j Immunol (1995) 25:2638–2642.
   PubMed Web of Science ®Google Scholar
• OSSEVOORT MA, FELTKAMP MCW, VAN VEEN KJH, MELIEF CJM, KAST WM: Dendritic cells as cariers for a cytotoxic T lymphocyte epitope based peptide vaccine in protection against a human papillomavirus type 16 induced tumor. J. Immunother. (1995) 18(2).
   Web of Science ®Google Scholar
• WANG TL, LING M, SHIH IM et al.: Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther. (2000) 7(9):726–733.
   PubMed Web of Science ®Google Scholar
• DA SILVA DM, SCHILLER JT, KAST WM: Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine (2003) 21(23):3219–3227.
   PubMed Web of Science ®Google Scholar